文献速递临床试验与 GCP

前瞻性识别治疗结局变量(PIVOT):针对加纳血红蛋白SC病儿童和成人的羟基脲随机安慰剂对照试验研究方案

Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease.
PubMed 文献 · Trials · 2023-09-22

PIVOT是一项随机、安慰剂对照、双盲临床试验,计划纳入约120名儿童和120名成人血红蛋白SC病患者,随机接受每日一次口服羟基脲或安慰剂治疗,初始剂量20±5 mg/kg/天,前6个月内可两次加量。主要目的为评估羟基脲毒性、对镰状细胞相关临床和实验室指标的影响,并识别适用于未来III期试验的研究终点。

要点

  • PIVOT旨在评估羟基脲治疗HbSC病的安全性和实验室及临床指标变化。
  • 约120名儿童和120名成人HbSC病患者将1:1随机接受羟基脲或安慰剂治疗。
  • 前12个月随机治疗,之后所有参与者可接受开放标签羟基脲治疗最长4年。

核心结论

  • PIVOT将确定羟基脲对HbSC病儿童和成人的安全性,并识别适合未来多中心III期临床试验的实验室和临床指标变化。

研究设计与样本

  • 随机、安慰剂对照、双盲临床试验,计划纳入约120名儿童和120名成人(5-50岁)HbSC病患者。
  • 筛查2个月后按1:1随机分配至每日一次口服羟基脲或安慰剂,初始剂量20±5 mg/kg/天,前6个月内可两次加量。
  • 随机双盲治疗12个月后,所有参与者可接受开放标签羟基脲治疗最长4年。

主要发现

  • 安全性结局包括治疗相关血细胞减少、全血黏度和不良事件。
  • 疗效结局包括随机治疗前12个月的血红蛋白和胎儿血红蛋白变化、经颅多普勒超声测量的颅内动脉速度、近红外光谱测定的脑氧合、超声测量的脾脏体积和肾脏大小、蛋白尿和视网膜成像。
  • 探索性结局包括使用ektacytometry进行红细胞变形性和点状镰状化的功能性红细胞分析、使用PROMIS问卷的患者报告结局和6分钟步行试验。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Haemoglobin SC (HbSC) is a common form of sickle cell disease (SCD), especially among individuals of West African ancestry. Persons with HbSC disease suffer from the same clinical complications and reduced quality of life that affect those with sickle cell anaemia (HbSS/Sβ0). Retrospective anecdotal data suggest short-term safety and benefits of hydroxyurea for treating HbSC, yet rigorous prospective data are lacking regarding optimal dosing, clinical and laboratory effects, long-term safety and benefits, and appropriate endpoints to monitor. Prospective Investigation of Variables as Outcomes for Treatment (PIVOT) was designed with three aims: (1) to measure the toxicities of hydroxyurea treatment on laboratory parameters, (2) to assess the effects of hydroxyurea treatment on sickle-related clinical and laboratory parameters, and (3) to identify study endpoints suitable for a future definitive phase III trial of hydroxyurea treatment of HbSC disease. METHODS: PIVOT is a randomised, placebo-controlled, double blind clinical trial of hydroxyurea. Approximately 120 children and 120 adults ages 5-50 years with HbSC disease will be enrolled, screened for 2 months, and then randomised 1:1 to once-daily oral hydroxyurea or placebo. Study treatment will be prescribed initially at 20 ± 5 mg/kg/day with an opportunity to escalate the dose twice over the first 6 months. After 12 months of blinded study treatment, all participants will be offered open-label hydroxyurea for up to 4 years. Safety outcomes include treatment-related cytopenias, whole blood viscosity, and adverse events. Efficacy outcomes include a variety of laboratory and clinical parameters over the first 12 months of randomised treatment, including changes in haemoglobin and fetal haemoglobin, intracranial arterial velocities measured by transcranial Doppler ultrasound, cerebral oxygenation using near infrared spectrometry, spleen volume and kidney size by ultrasound, proteinuria, and retinal imaging. Exploratory outcomes include functional erythrocyte analyses with ektacytometry for red blood cell deformability and point-of-sickling, patient-reported outcomes using the PROMIS questionnaire, and 6-min walk test. DISCUSSION: For children and adults with HbSC disease, PIVOT will determine the safety of hydroxyurea and identify measurable changes in laboratory and clinical parameters, suitable for future prospective testing in a definitive multi-centre phase III clinical trial. TRIAL REGISTRATION: PACTR, PACTR202108893981080. Registered 24 August 2021, https://pactr.samrc.ac.za.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Smart LR, Segbefia CI, Latham TS, et al. Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease. Trials. 2023. PMID: 37737189. doi:10.1186/s13063-023-07649-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。